SCHEMBL4091424

SCHEMBL4091424

Cc1cc(F)ccc1C(=O)CCC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.62
KMT2A Q03164 4/20 0.56
MEN1 O00255 1/20 0.56
FFAR1 O14842 2/20 0.43
FFAR4 Q5NUL3 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
ACKR3 P25106 1/20 0.43
MMP1 P03956 1/20 0.41
PPARG P37231 1/20 0.41
USP5 P45974 1/20 0.41
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GLA P06280 1/20 0.41
POLB P06746 1/20 0.41
CYP2D6 P10635 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22097354 0.86 KMT2A (0.70) HTTKMT2AMEN1FFAR1FFAR4
SCHEMBL21482768 0.84 HTR7 (0.47) HTTKMT2ANPC1RAB9AACKR3
SCHEMBL31661658 0.82 KMT2A (0.74) HTTKMT2AMEN1NPC1RAB9A
SCHEMBL3519350 0.82 KMT2A (0.74) HTTKMT2AMEN1NPC1RAB9A
SCHEMBL3527017 0.82 CES2 (0.57) HTTKMT2AMEN1ACKR3ALDH1A1
SCHEMBL31661842 0.82 CES2 (0.57) HTTKMT2AMEN1ACKR3ALDH1A1
SCHEMBL11582932 0.81 HTT (0.49) HTTKMT2AMEN1NPC1RAB9A
SCHEMBL8019351 0.81 HTT (0.64) HTTKMT2AMEN1NPC1RAB9A
SCHEMBL12780437 0.80 HSP90AB1 (0.47) HTTALDH1A1HSD17B10POLBL3MBTL1
SCHEMBL23891802 0.80 NPC1 (0.49) HTTNPC1RAB9AACKR3MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186900-A1 COMPOUND STERIX LIMITED (GB) 2009-07-23 US disclosed
EP-2013176-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER Sterix Limited (GB) 2009-01-14 EP disclosed
WO-2007096647-A2 DIARYL COMPOUNDS AS NON-STEROIDAL INHIBITORS OF 17-BETA HYDROXYSTEROID DEHYDROGENASE AND/OR STEROID SULPHATASE FOR THE TREATMENT OF OESTROGEN-RELATED DISEASES SUCH AS HORMONE DEPENDENT BREAST CANCER STERIX LIMITED (GB) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186900-A1 COMPOUND HSD17B2, HSD17B11, CYP17A1 HTT 1137/4885KMT2A 2145/4885MEN1 1122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.